Aratana Therapeutics, Inc.
Period: Mar 16, 2015 to Feb 3, 2017
Lead Plaintiff Deadline: Apr 7, 2017
Summary of Case:
A securities class action has been filed against Aratana Therapeutics, Inc. ("Aratana") on behalf of all persons who purchased or otherwise acquired PSTX securities between March 16, 2015 through February 3, 2017. This case has been filed in the USDC - NY Southern.
The complaint alleges that Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (ii) consequently, ENTYCE was not likely to be commercially available until late 2017; (iii) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (iv) as a result of the foregoing, Aratana's public statements were materially false and misleading at all relevant times.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.